4.6 Article

Deep-Learning Radiomics for Discrimination Conversion of Alzheimer's Disease in Patients With Mild Cognitive Impairment: A Study Based on 18F-FDG PET Imaging

Journal

FRONTIERS IN AGING NEUROSCIENCE
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2021.764872

Keywords

deep learning radiomics; F-18-fluorodeoxyglucose positron emission tomography; mild cognitive impairment; Alzheimer's disease; classification

Funding

  1. scientific development projects from ChenZhou Municipal Science and Technology Bureau
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI)
  3. National Institutes of Health
  4. Department of Defense
  5. National Institute of Aging and the National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica Inc.
  11. Biogen
  12. GE Healthcare
  13. Bristol-Myers Squibb Company
  14. IXICO Ltd.
  15. CereSpir Inc.
  16. Janssen Alzheimer Immunotherapy Research & Development LLC.
  17. Eisai Inc
  18. Johnson & Johnson Pharmaceutical Research &Development LLC.
  19. Elan Pharmaceuticals Inc.
  20. Lumosity, Lundbeck
  21. Eli Lilly and Company
  22. Merck Co. Inc.
  23. F. Hoffmann-La Roche Ltd.
  24. Meso Scale Diagnostics LLC
  25. Genentech Inc.
  26. NeuroRx Research
  27. Fujirebio
  28. Neurotrack Technologies
  29. Novartis Pharmaceuticals Corporation,
  30. Pfizer Inc.
  31. Piramal Imaging
  32. Takeda Pharmaceutical Company
  33. Canadian Institutes of Health Research are providing funds
  34. [Apr19 14 AG024904]

Ask authors/readers for more resources

The deep-learning radiomics (DLR) model based on F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) images combined with clinical parameters (DLR+C) showed superior classification performance in predicting conversion from MCI to AD. This novel approach provides a valuable quantitative biomarker for the computer-assisted diagnosis of AD conversion in MCI patients.
Objectives: Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and the most common form of dementia in the older people. Some types of mild cognitive impairment (MCI) are the clinical precursors of AD, while other MCI forms tend to remain stable over time and do not progress to AD. To discriminate MCI patients at risk of AD from stable MCI, we propose a novel deep-learning radiomics (DLR) model based on F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) images and combine DLR features with clinical parameters (DLR+C) to improve diagnostic performance.Methods: F-18-fluorodeoxyglucose positron emission tomography (PET) data from the Alzheimer's disease Neuroimaging Initiative database (ADNI) were collected, including 168 patients with MCI who converted to AD within 3 years and 187 patients with MCI without conversion within 3 years. These subjects were randomly partitioned into 90 % for the training/validation group and 10 % for the independent test group. The proposed DLR approach consists of three steps: base DL model pre-training, network features extraction, and integration of DLR+C, where a convolution network serves as a feature encoder, and a support vector machine (SVM) operated as the classifier. In comparative experiments, we compared our DLR+C method with four other methods: the standard uptake value ratio (SUVR) method, Radiomics-ROI method, Clinical method, and SUVR + Clinical method. To guarantee the robustness, 10-fold cross-validation was processed 100 times.Results: Under the DLR model, our proposed DLR+C was advantageous and yielded the best classification performance in the diagnosis of conversion with the accuracy, sensitivity, and specificity of 90.62 +/- 1.16, 87.50 +/- 0.00, and 93.39 +/- 2.19%, respectively. In contrast, the respective accuracy of the other four methods reached 68.38 +/- 1.27, 73.31 +/- 6.93, 81.09 +/- 1.97, and 85.35 +/- 0.72 %. These results suggested the DLR approach could be used successfully in the prediction of conversion to AD, and that our proposed DLR-combined clinical information was effective.Conclusions: This study showed DLR+C could provide a novel and valuable method for the computer-assisted diagnosis of conversion to AD from MCI. This DLR+C method provided a quantitative biomarker which could predict conversion to AD in MCI patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available